<DOC>
	<DOCNO>NCT02799615</DOCNO>
	<brief_summary>This multicenter study conduct determine whether infliximab exposure initial infusion predictive early clinical response hospitalize pediatric patient severe steroid-refractory UC IBD-U . This pilot feasibility study establish infrastructure , demonstrate feasibility , collect preliminary data support full study .</brief_summary>
	<brief_title>Anti-TNF Therapy Refractory Colitis Hospitalized Children</brief_title>
	<detailed_description>This multicenter prospective non-interventional cohort study identify clinical biological marker predict non-response hospitalized pediatric patient severe corticosteroid-refractory UC inflammatory bowel disease unspecified ( IBD-U ) initiate infliximab . Patients hospitalize severe UC IBD-U ( PUCAI ≥ 65 admission ) fail intravenous corticosteroid eligible . Blood , stool , rectal biopsy ( sigmoidoscopy perform clinical indication ) collect translational study ( Aim 3 ) . Patients receive infliximab per dose regimen determine clinical physician . No standard dose regimen use dose IFX determine treat physician . Serial PUCAI score infliximab level obtain . Those eligible participate serial blood sample take association drug infusion perform pharmacokinetic/pharmacodynamic modeling infliximab exposure . Clinical response determine use Pediatric UC Activity Index ( PUCAI ) questionnaire . Initially , 6 center participate minimum target enrollment goal 36 evaluable pediatric research participant ( maximum 40 ) age &gt; 4 year &lt; 18 year old UC IBD-U ( average 6/center ) . The primary endpoint relationship IFX exposure ( area curve PK model ) Day 7 clinical response define Pediatric Ulcerative Colitis Activity Index ( PUCAI ) ≤ 35 . Secondary endpoint Week 8 clinical remission , Week 26 steroid-free , colectomy-free remission . We initially enlist 6 center , enroll 36-40 evaluable patient 2 year . This study describe protocol design pilot feasibility study , anticipate ultimately expand large study . Therefore , demonstrate feasibility begin development biorepository patient population , certain biospecimens collect study anticipated future translational study follow : - Blood use IFX pharmacokinetic assay ( e.g . level , antibody ) future biomarker discovery . - Blood DNA anticipate use genotype/phenotype correlation genetic predictor rapid infliximab clearance non-response . - Colon tissue RNA use determine local gene expression pattern predict explain infliximab clearance non-response . - Colon tissue DNA anticipate use study microbiome epigenetic change relate severe UC response infliximab . - Colon tissue use determine relationship tissue TNF level ( protein ) infliximab clearance non-response . - Stool collect serial measurement fecal calprotectin future microbiome study</detailed_description>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Age criterion : &gt; 4 &lt; 18 year age 2 . Diagnosis UC IBDU establish criteria25 3 . Admitted hospital 4 . Colitis extend beyond rectosigmoid colon 5 . PUCAI &gt; 65 admission ≥ 45 &gt; 3 day corticosteroids 6 . Treatment infliximab consider treat physician 7 . Anticipated followup &gt; 6 month infliximab initiation 8 . Permission/assent parent/guardian research participant . 1 . Diagnosis Crohn 's disease 2 . Enteric infection bacterial pathogen ( include clostridium difficile ) , per review medical record 3 . Colon tissue positive CMV PCR , immunohistochemistry , situ hybridization , per review medical record 4 . Colitis currently extend rectosigmoid colon ( proctosigmoiditis ) 5 . Prior treatment infliximab antiTNF agent 6 . Prior treatment cyclosporine tacrolimus 7 . PUCAI &lt; 45 day first infliximab infusion 8 . Pregnancy , per review medical record verbal report 9 . Other poorly control medical condition 10 . Hepatic disease ( AST Alk Phos &gt; 3 time upper limit normal ) absence IBD associate liver disease 11 . Renal disease ( BUN creatinine &gt; 1.5 time upper limit normal )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>